2020 Outlook: 20 HTA Challenges and 20 PSE Solutions

2020 Outlook: 20 HTA Challenges and 20 PSE Solutions

As we embark on a new decade, we here at #PSEconomics have been reflecting on how far the young discipline of HEOR and HTA has evolved in a very short time. CADTH was a trailblazer, established in 1989 as a 3-year pilot program to evaluate medical devices. The year 1995 brought the Association for Pharmacoeconomics and Outcomes Research (APOR), now known as ISPOR. NICE was established in 1999 and issued its first technology appraisal--on wisdom tooth extraction--in 2000. Now, in 2020, health economics is a recognized academic discipline, and every major pharmaceutical company has a team of HEOR experts to guide global and local HTA strategy, supported by external partners who generate and communicate evidence to support market access for life-changing therapies.

Our field has grown quickly, and there are many challenges ahead. In 2020, we plan to share a series of 20 articles on the key challenges in HTA, with expert insights on solutions and strategies. For example:

  • Outdated SLRs: Research in oncology is moving fast, meaning that patients can access more innovative treatments than ever before. The speed of discovery does, however, pose challenges for the HTA lead who needs to maintain up-to-date systematic literature reviews.
  • Single Arm Comparisons: Recognizing the need to bring drugs to market in a timely and ethical manner, regulatory agencies have been willing to grant approval based on single-arm studies in certain cancers and rare diseases. This type of clinical evidence poses challenges for comparative effectiveness research, often required by HTA bodies.
  • GVDs Not User-friendly: The global value dossier (GVD) has become a standard component of value & access, providing a comprehensive review of the evidence supporting product value. Ideally, a GVD is just a short step along the path to HTA submissions. In practice, a GVD can become long and unwieldy, and even the most user-friendly GVD can become outdated quickly in a dynamic market environment.
  • "Black-box" BIMs: Budget impact models (BIMs), another core component of a health economic evidence portfolio, can become the target of payer skepticism. How can we ensure that a BIM is methodologically sound and comprehensive while maintaining full transparency on the design and inputs?
  • TMI of Conference Presentations: Alongside the growth of online information sources, conferences continue to be important opportunities for professional networking, along with presenting emerging research. Given the lag time from conference presentation to journal publication (if the results are indeed ever published), how can the astute HTA lead stay abreast of information presented at conferences?
No alt text provided for this image

These and other challenges present an opportunity for collaborative problem solving. We look forward to engaging in these discussions with you in the coming year. Watch this space!

要查看或添加评论,请登录

Anna Forsythe的更多文章

  • AI vs. Systematic Literature Reviews: Why Not Both?

    AI vs. Systematic Literature Reviews: Why Not Both?

    Recently, I’ve seen a growing debate: Should we rely on quick AI-based tools like ChatGPT, or stick with traditional…

    5 条评论
  • OncoScope-AI: A Personal Mission to Change Cancer Care

    OncoScope-AI: A Personal Mission to Change Cancer Care

    Two years ago, a 52-year-old friend of mine died of breast cancer. She had confided in me – and no one else – about her…

    39 条评论
  • 2020 Outlook: SLR challenges and LiveSLR? solutions

    2020 Outlook: SLR challenges and LiveSLR? solutions

    A systematic literature review is a critical component of many health technology assessment submissions. It’s a…

    2 条评论
  • PSE: EXPLORING THE EVIDENCE

    PSE: EXPLORING THE EVIDENCE

    Meet PSE Health Economic Experts: Gabriel Tremblay and Mike Dolph at ISPOR EU 2019 to discuss the Indirect Treatment…

    1 条评论
  • No time to hibernate, it’s almost Breast Cancer Awareness Month!

    No time to hibernate, it’s almost Breast Cancer Awareness Month!

    To take on the second deadliest cancer in woman, is pushing health economics and outcomes research ever forward. Over…

  • NICE Recommends Midostaurin in AML

    NICE Recommends Midostaurin in AML

    Breaking News: Midostaurin, a multi-targeted protein kinase inhibitor, has received a positive recommendation from NICE…

    1 条评论
  • Medical Writer Opening with PSE

    Medical Writer Opening with PSE

    We are a fast-growing Health Economics Consultancy firm with experts in New York, Cambridge, London, Manchester…

  • Number needed to treat in indirect treatment comparison

    Number needed to treat in indirect treatment comparison

    Therapeutic Area: Oncology, Radioiodine-Refractory Differentiated Thyroid Cancer (RR-DTC) Type of Study: Indirect…

    1 条评论
  • 4 Misconceptions about Your Preferred HEOR Vendor

    4 Misconceptions about Your Preferred HEOR Vendor

    The HEOR sector has seen enormous changes in the past few years, particularly with submission requirements and…

    4 条评论
  • Purple Squirrel Economics publishes study in the Journal of ClinicoEconomics and Outcomes Research

    Purple Squirrel Economics publishes study in the Journal of ClinicoEconomics and Outcomes Research

    Purple Squirrel Economics January, 2018 - Dr. Anna Forsythe co-authored a study on Systematic Literature Review of…

    1 条评论

社区洞察

其他会员也浏览了